vs 7.71%, respectively; P=0.0192), week 6 (18.81% vs 14.03%, respectively; P=0.0390), and week 12 (33.42% vs 20.77%, respectively; P<0.0001) for chest acne (Table 2; Figure 2C). IGA success at week 9 was numerically higher, but not significantly different in the sarecycline group compared to the placebo group (25.07% vs 20.21%, respectively; P=0.0759).
Pooled IGA Success in Back Acne
In the individual studies, IGA success rate was significantly greater in the sarecycline group compared to the placebo group at weeks 3 (10.6% vs 5.2%, respectively; P=0.011), 6 (17.5% vs 10.9%, respectively; P=0.046), 9 (28.1% vs 17.2%, respectively; P=0.006) and 12 (32.9% vs 17.1%, respectively; P<0.001) for